AGR2在卵巢癌组织中表达及临床意义

Expression and clinical significance of AGR2 in ovarian carcinoma

目的:通过分析人前梯度蛋白2(AGR2)在不同卵巢组织中的表达及其与卵巢癌各临床病理参数间的关系,探讨AGR2在卵巢癌发生、发展中的作用。方法:采用免疫组化SP法检测AGR2在15例正常卵巢组织、20例卵巢良性肿瘤组织及50例卵巢癌组织中的表达情况,并结合卵巢癌各临床病理参数进行分析。结果:AGR2在卵巢癌组织中的表达水平明显高于卵巢正常组织和卵巢良性肿瘤组织(P<0.05);AGR2在卵巢癌组织中表达水平与患者的年龄、文化程度及病理类型无关(P>0.05),而与患者的临床分期、淋巴结转移密切相关(P<0.05)。结论:AGR2有望成为卵巢癌早期诊断的一种新的肿瘤标记物。

Objective：To investigate the expression of anterior gradient 2（AGR2） in different ovarian tissues and its relationship with clinicopathological parameters,and to detect the role of AGR2 in the occurrence and development of ovarian cancer.Methods：Immunohistochemical SP method was used to detect the expression of AGR2 in 15 cases of normal ovarian tissue,20 cases of benign ovarian tumor and 50 cases of ovarian cancer,and the clinical pathological parameters of ovarian cancer were analyzed.Results：The expression of AGR2 in ovarian cancer tissues was significantly higher than that in normal ovarian tissues and benign ovarian tumors（P〈0.05）.The expression level of AGR2 in ovarian cancer was not related to the age,degree of education and type of pathology（P〈0.05）,but was closely related to the clinical stage and lymph node metastasis（P〈0.05）.Conclusion：AGR2 is expected to be a new tumor marker for early diagnosis of ovarian cancer.